G-protein coupled receptor (GPCR) kinase-2 interacting protein 1 (GIT1) is a multifunctional scaffolding protein that regulates epidermal growth factor receptor (EGFR) signaling pathways. We demonstrate that GIT1 interacts with sorting nexin 6 (SNX6), a member of the SNX family that increases EGFR trafficking between endosomes and lysosomes, thereby enhancing EGFR degradation. The GIT1-SNX6 interaction is increased 3-fold after treatment with EGF for 60 min. The second coiled-coil domain (CC2; aa 424 -474) of GIT1 mediates binding to SNX6. Subcellular fractionation and confocal microscopy data indicate that GIT1 and SNX6 interact in endosomes. Knockdown of GIT1 expression by small interfering RNA decreased the rate of EGF-induced EGFR degradation. Expression of exogenous GIT1 or SNX6 alone did not alter EGFR degradation; however, coexpression of GIT1 and SNX6 decreased EGFR levels both basally and in response to EGF. In contrast, expression of GIT1(CC2 deleted) and SNX6 did not reduce EGFR levels, demonstrating that the interaction between GIT1 and SNX6 was required to regulate EGFR trafficking. Phosphorylation of the EGFR substrate phospholipase C-␥ was decreased by coexpression of GIT1 and SNX6. These data demonstrate an endosomal, EGF-regulated interaction between SNX6 and GIT1 that enhances degradation of the EGFR, and thereby alters EGFR signaling. Our findings suggest a new role for GIT1 in tyrosine kinase receptor trafficking.-Cavet, M. E., Pang, J., Yin, G., Berk, B. C. An epidermal growth factor (EGF) -dependent interaction between GIT1 and sorting nexin 6 promotes degradation of the EGF receptor. FASEB J.
G-protein coupled receptor (GPCR) kinase-2 interacting protein 1 (GIT1) was first identified as a GPCR kinase-2 binding protein that inhibited the agonist promoted sequestration of the ␤2-adrenergic receptor from the cell surface. Through inhibition of ADPribosylation factor 6 (ARF6) activity, GIT1 prevents the endocytosis of receptors internalized through the clathrin-coated pathway, including GPCRs and the tyrosine kinase receptor, EGFR (epidermal growth factor receptor) (1) (2) (3) . GIT1 has multiple cellular locations, including cytoplasm, focal adhesions, and endosomes, consistent with multiple functions within the cell (3) (4) (5) . These functions include acting as a scaffold to promote activation of mitogen-activated protein kinase/ERK kinase (MEK1) and extracellular signal-related kinase (ERK1/2) (6), and regulation of focal adhesion dynamics and cell motility through association with proteins of focal complexes such as p21 GTPase-activated kinase (PAK), PAK-interacting exchange factor (PIX), and paxillin (3, (7) (8) (9) (10) . GIT1 is therefore an integrator of signaling pathways, controlling vesicle trafficking, adhesion, and cytoskeletal organization.
The sorting nexins (SNXs) are a family of cytoplasmic and early endosome-associated proteins shown to function in the intracellular trafficking of plasma membrane receptors (11, 12) . SNX1 was cloned in a yeast two-hybrid assay as a binding partner for the cytoplasmic domain of the EGFRs (13) . Overexpression of SNX1 increased EGFR degradation, suggesting a role for SNX1 in targeting EGFRs to the lysosome (13) . SNX6 is structurally related to SNX1 in that it contains a Phox homology domain (shared among all 17 SNXs) and 2 coiled-coil (CC) regions within a large carboxyl terminus (14) . SNX6 interacts with receptors for EGF, insulin, platelet-derived growth factor, transferrin, leptin, and transforming growth factor-␤ (TGF-␤). Overexpression of SNX6 decreases TGF-␤ signaling, suggesting an increase in receptor degradation (14) .
In the present study, we demonstrate an EGF-dependent interaction between GIT1 and SNX6 by biochemical and immunofluorescence techniques. Previous studies demonstrated that SNXs and GIT1 are both located to endosomes (11, 12) . SNXs increase receptor degradation, and SNX binding partners are known to alter EGFR degradation rate (15) (16) (17) . Therefore, our hypothesis was that the GIT1/SNX6 interaction would alter EGFR degradation. We demonstrate that reducing GIT1 expression using small interfering RNA (siRNA) decreased degradation of the EGFR. Furthermore, expression of exogenous GIT1 and SNX6 decreased cellular EGFR levels, suggesting that the GIT1 interaction with SNX6 enhances EGFR degradation. Multiple studies have shown that EGFR can signal both at the cell surface and in endosomal compartments. Therefore, alterations in the trafficking of the EGFR likely control EGFR signal intensity and duration (18, 19) . We found that the interaction between SNX6 and GIT1 decreased phospholipase C-␥ (PLC␥) phosphorylation in response to EGF, demonstrating that increased degradation of the EGFR correlates with reduced receptor signaling. This is a new mechanism by which GIT1 regulates intracellular receptor trafficking, distinct from its role as a modulator of plasma membrane receptor internalization.
MATERIALS AND METHODS

Plasmid cDNAs and siRNA
The mGIT1-expressed sequence tag clone (GenBank accession number AI414223) was purchased from Invitrogen (Carlsbad, CA, USA) and completely sequenced. The clone lacked the last 200 bp of the C-terminal open reading frame. Therefore, the missing C-terminal fragment was obtained by a reverse transcriptase reaction using mouse brain total RNA and specific primers (5Ј-CTGAGCTGGAGAGCTTAGATGG-AGACC-3Ј and 5Ј-GCTCTAGAGGTCCCAGGGTGT GGGTA-AGGGCAG-3Ј). Then, full-length mouse GIT1 [GIT1(WT)] was cloned into the NotI and XbaI sites of Xpress-pcDNA3.1 vector (Invitrogen) [resulting in Xpress-GIT1(WT)]. Using polymerase chain reaction (PCR), GIT1(1-635 aa), GIT1(1-420 aa), and GIT1(420 -770 aa) were cloned into XpresspcDNA3.1 vector [resulting in Xpress-GIT1(1-635 aa), Xpress-GIT1(1-420 aa), and Xpress-GIT1(420 -770 aa)]. Xpress-GIT1 with CC2 domain deleted [Xpress-GIT1(⌬CC2)] was obtained using Excite mutagenesis kit (Stratagene, La Jolla, CA, USA). pEBB-Flag-SNX6 cDNAs were a generous gift from Tony Parks and Carol Renfrew Haft (U.S. National Institutes of Health, Bethesda, MD, USA). To synthesize GST-SNX6 (73-406) using PCR, the SNX6 fragment was cloned into pGEX-2KG vector. All constructs were confirmed by sequencing.
Rat GIT1 siRNA sequence (AAGCTGCCAAGAAGAAGC-TAC) and a control nonsilencing siRNA (AATTCTCCGA-CACGTGTCACT) were designed as described previously (10) and synthesized by Ambion (Austin, TX, USA). GIT1 siRNA (100 nM) was transfected into vascular smooth muscle cells (VSMCs) using Fugene (Roche Diagnostics, Indianapolis, IN, USA) according to the manufacturer's protocol. Cells were used for experiments 72 h after transfection.
Yeast two-hybrid screen
Full length mouse GIT1 cDNA was generated by PCR, and the fragment was cloned into pGBKT7 vector, resulting in the GIT1 bait expression construct (pGBKT7-GIT1). The insert sequence and reading frame were confirmed by sequencing. For the two-hybrid screen, the yeast strain AH109 was transformed sequentially with pGBKT7-GIT1 and an 11-day mouse embryo cDNA library (Clontech, Mountain View, CA, USA).
From 1 ϫ 10 6 clones, 1200 positive-testing clones were grown on synthetic dropout (SD)/Trp-Leu-Ade-His-. When a colonylift filter assay designed to detect ␤-galactosidase activity was used, only 150 positive-testing clones were obtained. Of these clones, 40 specifically interacted with GIT1 in yeast AH109/ Y18 mating tests. Sequence analysis and bioinformatics studies indicated that 5 of 40 GIT1-interacting sequences represented SNX6.
Cell culture
Cultured VSMCs were obtained from rat aorta as described previously (20, 21) . VSMCs, rat pulmonary artery smooth muscle cells (PACs), and HEK293 cells were grown in Dulbecco's modified Eagle's medium supplemented with 25 mM NaHCO 3 , 10 mM HEPES (pH 7.4), 50 IU/ml penicillin, 50 g/ml streptomycin, and 10% fetal bovine serum (FBS) in a 5% CO 2 /95% O 2 incubator at 37°C.
In vitro translation of full-length GIT1
Full length Xpress-GIT1 under control of the T7 promoter in Xpress-pcDNA3.1 vector was transcribed and translated in vitro using the TNT T7-coupled reticulocyte lysate system (Promega, Madison, WI, USA). Briefly, 40 l of TNT Quick Master Mix, 1 l of methionine (1 mM), and 1 g of template DNA were mixed in 50 l, incubated for 90 min at 30°C, and immediately used for the binding assays.
Immunoprecipitations and pulldowns
Cell monolayers were rinsed with ice-cold phosphate-buffered saline (PBS; 150 mM NaCl, 20 mM Na 2 PO 4 , pH 7.4) and then scraped in 1 ml of PBS. After a brief centrifugation, the cells were solubilized in 1 ml of cell lysis buffer [10 mM HEPES, pH 7.4; 50 mM Na pyrophosphate; 50 mM NaF; 50 mM NaCl; 5 mM EDTA; 5 mM EGTA; 1 mM Na 3 VO 4 ; and 0.5% Triton plus 1:1000 protease inhibitor cocktail (PIC; Sigma, St. Louis, MO, USA)]. Cells were sonicated for 20 s, agitated on a rotating rocker at 4°C for 30 min, and centrifuged at 12,000 g for 30 min to remove insoluble cellular debris.
For coimmunoprecipitation studies, HEK293 cells were cotransfected with different plasmids. Immunoprecipitations were carried out by preclearing cell lysates with protein A/G agarose (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h, followed by incubation with anti-Xpress antibody for 3 h, and protein A/G agarose for a further 1 h or M2 antiflag agarose beads for 4 h. Pulldowns were performed by incubating 10 g of GST-SNX6 (73-406) or GST as a control bound to glutathione-sepharose with in vitro translated Xpress-GIT1 overnight at 4°C. Immunoprecipitates or pulldowns were then washed 4 times with 1 ml cell lysis buffer before the addition of Laemmli sample buffer. After heating at 95°C for 3 min, proteins were resolved on SDS-PAGE and transferred to nitrocellulose membranes for Western blot analysis.
Immunoblotting was performed with Xpress antibody (Invitrogen); M2 flag antibody (Sigma); GIT1 antibody (BD Transduction Labs, Lexington, KY, USA); SNX6 antibody (Zymed, San Francisco, CA, USA); EGFR antibody, angiotensin II type 1 receptor (AT1R) antibody, and actin antibody (Santa Cruz). Immunoreactive bands were detected with horseradish peroxidase (HRP) -conjugated secondary antibodies (Amersham Pharmacia, Piscataway, NJ, USA) and enhanced chemiluminescence.
Tris-HCl, pH 7.4, and lysed by 25 strokes with a Dounce homogenizer and 10 passes through a 25-gauge needle. Postnuclear supernatants were obtained by centrifuging at 1000 g for 5 min. The supernatant was placed on the top of a 10 -40% linear Optiprep gradient (Sigma) and centrifuged at 4°C for 20 h at 55,000 g in an SW40 rotor (Beckman Instruments, Palo Alto, CA, USA). Gradients were harvested in 300 l fractions and analyzed by SDS-PAGE. Subcellular localization of SNX6 and GIT1 was compared with that of markers for early endosomes [early endosome antigen 1 (EEA1) antibody; BD Transduction Labs], recycling endosomes (transferrin receptor; Zymed) and lysosomes [lysosomal associated membrane protein-2 (Lamp2); Developmental Studies Hybridoma Bank, Iowa City, IA, USA].
Immunocytochemistry and confocal microscopy
PACs seeded on glass coverslips were transfected with Xpress-GIT1 and Flag-SNX6 using Lipofectamine 2000 (Invitrogen). After 24 h, cells were serum starved for a further 12 h, then treated with EGF for 0, 30, and 60 min. Cells were fixed in 3% paraformaldehyde, permeabilized with 0.2% Triton, and blocked in PBS with 5% FBS and 0.2% bovine serum albumin. Cells were costained with Flag antibody to visualize SNX6, GIT1 antibody (QCB) and EEA1, then incubated in Alexa secondary antibodies (Molecular Probes, Eugene, OR, USA). Images were acquired using an Olympus IX70 Fluoview confocal microscope (Olympus, Tokyo, Japan).
RESULTS
Identification of SNX6 as a GIT1 binding protein by yeast two-hybrid screen and GST pulldown
To identify proteins that interact with GIT1, we screened a GAL4 activation domain fusion library of mouse embryo cDNA using a full-length GIT1 GAL4 binding domain construct as bait. From 1 ϫ 10 6 clones screened, 150 positive clones were identified, and 40 were confirmed by genetic complementation. Among these clones, 33 encoded proteins with annotated functions, and 7 were expressed sequence tags. There were 5 clones whose sequences were identical to SNX6, although none were full length. As shown in Fig. 1 , GIT1 (pGBKT7-GIT1) interacted with SNX6 (pACT2-SNX6) to the same extent as positive controls (pG-BKT7-53 and pACT2-TD1-1). SNX6 did not interact with the GAL4 DNA binding domain alone (pGBKT7).
To demonstrate that the interaction between SNX6 and GIT1 was direct, full-length Xpress-GIT1 was synthesized by in vitro translation, and its ability to bind to GST-SNX6 (73-406) was determined. Binding between translated GIT1 and GST-SNX6 (73-406) was strong compared to minimal binding to GST alone (Fig. 1B) , indicating a direct interaction between GIT1 and SNX6.
GIT1 associates with SNX6 in an EGF sensitive manner
The interaction between GIT1 and SNX6 was investigated by performing immunoprecipitation in HEK293 cells. Cells were transfected with Flag-SNX6 and Xpress-GIT1, and then immunoprecipitation with Flag antibody was performed. As shown in Fig. 2A , SNX6 and GIT1 interacted in HEK293 cells. The interaction was enhanced on EGF stimulation by 1.9-fold at 30 min and 3.1-fold at 60 min (Fig. 2B) . To confirm the endogenous interaction between SNX6 and GIT1, SNX6 was immunoprecipitated in VSMCs, followed by Western blotting for GIT1. As shown in Fig. 2C , GIT1 was present in the immunoprecipitate (left panel). After the reverse immunoprecipitation of GIT1, SNX6 could be detected in the immunoprecipitate (Fig. 2C , right panel). Similar to HEK293 cells, the interaction of endogenous proteins in VSMCs was enhanced on EGF stimulation by 1.7-fold at 30 min, 3.8-fold at 60 min, and 2.2-fold at 90 min (Fig. 2D) .
Determination of domains of GIT1 that mediate interaction with SNX6
To define domains of GIT1 involved in the interaction with SNX6, GIT1 deletion mutants were expressed in HEK293 cells, and the ability of SNX6 to interact was determined by immunoprecipitation and Western blotting. The amino-terminal half of GIT1 contains a zinc finger-like motif responsible for the ARF GTPase-activating (GAP) activity, followed by ankyrin repeat units (Fig. 3A) . Within the GIT1 structure, there are three putative CC domains: CC1 (aa 254 -274), which is within the SHD1 (yeast Spa2 homology domain; aa 255-396); CC2 (aa 424 -474); and CC3 (aa 649 -669). Genetic complementation in yeast and GST pulldown demonstrate specific interaction between SNX6 and GIT1. A) Complementation analysis was performed as described in Materials and Methods. The positive control is p53 protein interacting with transcription factor TD-1 (pGBKT7-p53ϩpACT2-TD1-1). The two negative controls are SNX6 interacting with vector alone (pGBKT7ϩpACT2-SNX6) and GIT1 interacting with vector alone (pGBKT7ϩpACT2). In contrast, SNX6 interacts with GIT1 (pGBKT7-GIT1ϩpACT2-SNX6) to the same extent as positive control. B) Xpress-GIT1 was synthesized by in vitro translation and incubated with GST alone or GST-SNX6 (73-406). Proteins bound to beads were subjected to SDS-PAGE and blotted with Xpress. C) Coomassie stain of GST-fusion proteins.
SNX6 interacted with GIT1(WT), GIT1 (1-635), and to a lesser extent with GIT1 (420 -770), but did not interact with GIT1 (1-420), demonstrating that the site of interaction is between aa 421 and 635 (Fig. 3B) . To define further the region of GIT1 that interacted with SNX6, the ability of SNX6 to interact with GIT1 deletion mutations of the CC1 and CC2 regions was determined. Although SNX6 coimmunoprecipitated with GIT1(WT) and GIT(⌬CC1) in an EGF-dependent manner (Fig. 3C) , GIT1(⌬CC2) did not immunoprecipitate with SNX6 (Fig. 3B, C, middle panel) , defining aa 424 -474 as the SNX6 binding domain.
Identify the binding domain of SNX6 that associates with GIT1
To characterize the binding domain of SNX6 that interacts with GIT1, several deletion mutants of SNX6 were prepared. SNX6 contains two major interaction domains; the Phox homology domain and two CC domains (CC1 and CC2; Supplemental Fig. 1A ). Deletion mutants were designed to define the effects of the Phox homology domain and the CC domains on binding to GIT1. The ability of GST-SNX6 constructs to pull down Xpress-GIT was determined. SNX6 mutants containing the CC domains [Flag-SNX6 (73-406), (153-406), and (253-406)] bound strongly to GIT1. In contrast, there was little or no binding to constructs containing the Phox domain [Flag-SNX6 (1-152) and (1-252)] or to GST alone (Supplemental Fig. 1B) . To study the domains involved in GIT1-SNX6 binding in vivo, Flag-tagged SNX6 constructs were immunoprecipitated, and interacting Xpress-GIT1 was detected using Xpress antibody. Mutants containing Phox domain alone (1-152 and 1-252) and also the CC domain alone (153-406 and 253-406) were able to bind to GIT1, indicating there are multiple domains on SNX6 that interact with GIT1 in vivo (Supplemental Fig. 1C ). Due to differing expression of the SNX6 mutants, the ratio of immunoprecipitated GIT1/SNX6 mutant expression was calculated ( Supplemental Fig. 1C ). Normalized to SNX6 expression levels, the ability of GIT1 to interact with SNX6 mutants containing the CC domains [Flag-SNX6 (73-406), (153-406) and (253-406)] was 2-fold greater than the Phox domain [Flag-SNX6 (1-152) and (1-252)]. Thus, the SNX6 CC domains are the dominant sites for GIT1 interactions.
Colocalization of SNX6 and GIT1 by immunofluoresence microscopy
Previous studies have demonstrated that SNX6 and other SNXs are localized to early endosomes (14, (22) (23) (24) . GIT1 is present in multiple intracellular locations, including focal adhesions, cytoplasm, and endocytotic vesicles (4) . To demonstrate the colocalization of SNX6 and GIT1, Flag-SNX6 and Xpress-GIT1 were transfected into PACs, and their intracellular distribu- tion was analyzed by confocal microscopy. Basally, GIT1 had a diffuse cytoplasmic staining, with some punctate structures and membrane staining, whereas SNX6 had a punctate vesicular staining (Fig. 4) . Under basal conditions, colocalization of SNX6 and GIT1 was infrequent and difficult to detect because of the high amount of cytosolic GIT1 (Fig. 4A-C) . In contrast, after stimulation with EGF, some vesicular staining for GIT1 was apparent, and this overlapped with the vesicular punctate staining for SNX6 (Fig. 4D-I ). This provides evidence for an in vivo vesicular interaction between SNX6 and GIT1. Because EGF treatment redistributed GIT1 to actin filaments (Supplemental Fig. 2C, I) , it also appears that colocalization occurs with cytoskeletal components.
Cofractionation of SNX6 with GIT1 and with early endosome markers
To study further the cellular distribution of endogenous SNX6 and GIT1, VSMCs were fractionated on a 10 -40% Optiprep gradient. The avian homologue of GIT1, p95-APP1, shuttles between the plasma membrane and an endocytic recycling compartment (3, 5, 25) . Therefore, we compared the localization of GIT1 and SNX6 with markers for early endosomes (EEA1), recycling endosomes (transferrin receptor), and lysosomes (Lamp2). Consistent with the data for SNX16 and SNX17 (26, 27) , SNX6 was mainly found in fractions of lower density under basal conditions (fractions 3-7), overlapping with EEA1staining basally (fractions 3-7) and also overlapping with GIT1 (fractions 3-6) (Fig. 5A, C) . In contrast, the transferrin receptor was mainly in fractions 7-9 and 14. After EGF treatment (10 ng/ml, 60 min), the majority of SNX6 and GIT1 was distributed in similar light fractions (GIT1; fractions 4 -6; SNX6; fractions 4 -7), which overlapped with EEA1 (fractions 3-7) but not the transferrin receptor, which was mainly in fractions 7-9 and 14 -15, or Lamp2, which was distributed in the heavier fractions (fractions 14 -18) . (Fig. 5B, C) . To quantitate the cofractionation of GIT1, SNX6, and EEA1, the overlapping areas (crosshatched in Fig. 5C ) were measured. After stimulation with EGF, cofractionation of SNX6 and GIT1 increased by 52%. This colocalization was consistent with translocation to endosomes, based on cofractionation of GIT1 and SNX6 with EEA1 after stimulation by EGF for 60 min (Supplemental Fig. 3 ). These results indicate that SNX6 and GIT1 reside in the same cellular compartments and after EGF treatment appear to be primarily in an endosomal compartment.
GIT1 interaction with SNX6 enhances the degradation of the EGFR and decreases EGFR signaling
SNXs are known to increase EGFR degradation by increasing transport to lysosomes (13, 28) . Several reports demonstrate that EGFR degradation is modified by specific interactions between SNXs and other proteins (15) (16) (17) . Given the increased interaction between SNX6 and GIT1 on EGF stimulation and the colocalization of the two proteins in an endosomal compartment, we hypothesized that the interaction between GIT1 and SNX6 would alter degradation of the EGFR. To provide evidence for a physiological function for GIT1 in EGFR degradation, the effect of depleting GIT1 on EGFR degradation was determined using GIT1 siRNA. Transfection of RASM with GIT1 siRNA caused an 80 Ϯ 6% decrease (nϭ5) in GIT1 expression (Fig. 6A, middle panel) . Knockdown of GIT1 did not alter basal EGFR levels. However, the EGF-induced degradation of the EGFR was significantly slower in RASM transfected with GIT1 siRNA as compared to control (Fig. 6A, B ). These data demonstrate that GIT1 plays a physiological role in the degradation of the EGFR.
To determine the effect of the SNX6-GIT1 interaction on EGFR degradation, we expressed exogenous SNX6 and GIT1 in PACs (Fig. 7) . Overexpression of GIT1 alone (group 2), or SNX6 alone (group 3) did not alter EGFR expression or degradation significantly. However, coexpression of GIT1(WT) and SNX6 in the same cells significantly reduced both the basal and stimulated EGFR expression [compare GIT1(WT) and SNX6 (group 4 vs. 1-3)]. In contrast, when GIT1(⌬CC2), which lacks the SNX6 binding domain, was coexpressed with SNX6, there was an increase in EGFR expression (group 5 vs. 4). To evaluate the effect of the GIT1 ARF-GAP domain, GIT1 (250 -770), which lacks the ARF-GAP domain, and SNX6 were cotransfected in PACs. GIT1 (250 -770) alone had little effect on EGFR degradation, similar to GIT1(WT) (group 7 vs. 3). However, cotransfection of GIT1 (250 -770) with SNX6 (group 8) caused a dramatic increase in EGFR degradation, similar to that seen with GIT1(WT). These data demonstrate that the interaction between SNX6 and GIT1 is required to decrease EGFR expression. Together with the intracellular vesicular colocalization of SNX6 and GIT1, this result suggests that the SNX6-GIT1 interaction increases EGFR degradation.
To demonstrate that GIT1/SNX6 overexpression did not cause nonspecific degradation of membrane proteins, expression of AT1R, a GPCR that is endocytosed and partly recycled to the plasma membrane after angiotensin II stimulation (29, 30) , was also determined after expression of exogenous GIT1/SNX6. Expression of GIT1 and SNX6 did not change cellular levels of the AT1R before or after angiotensin II stimulation (Fig. 7C) .
To determine the functional consequence of this reduction in EGFR expression, autophosphorylation of Figure 6 . GIT1 siRNA reduces EGF-induced degradation of the EGFR. GIT1 siRNA or control siRNA was transfected into RASM. At 72 h after transfection, cells were stimulated with 10 ng/ml EGF for the indicated times. A) Cells were harvested and 30 g of cell lysates was subjected to SDS-PAGE, followed by Western blotting for the EGFR (top panel), GIT1 (middle panel) and actin (bottom panel). B) Densitometric analysis of EGFR expression, expressed as amount relative to control (0 min EGF). Open bars ϭ control siRNA; solid bars ϭ GIT1 siRNA. *P Ͻ 0.05 vs. control at that time point; n ϭ 3. Interaction between GIT1 and SNX6 decreases EGFR expression. A) PACs were transfected with GIT1 and SNX6 constructs as indicated. After overnight serum starvation, cells were stimulated with 10 ng/ml EGF for the indicated times. Cells were harvested and 30 g of cell lysates was subjected to SDS-PAGE, followed by Western blotting for EGFR (top panel), GIT1 (middle panel), and SNX6 (bottom panel). B) Densitometric analysis of EGFR expression, expressed as amount relative to control (0 min EGF). Solid bars ϭ basal; open bars ϭ 30 min EGF treatment; striped bars ϭ 60 min EGF treatment. *P Ͻ 0.05 vs. control, 0 min; P Ͻ 0.01 vs. control, 30 min; Ꭽ P Ͻ 0.01 vs. control, 60 min; n ϭ 4. C) Cells were transfected as in A and were stimulated with 100 nM angiotensin II (AngII) for the indicated times. Cells were harvested, subjected to SDS-PAGE, followed by Western blotting for the AT1R (top panel), GIT1 (middle panel), and SNX6 (bottom); n ϭ 2.
the EGFR and phosphorylation of the EGFR substrate PLC␥ were determined after cotransfection of SNX6 and GIT1 in PACs. SNX6 and GIT1 expression reduced the expression of the EGFR. When normalized for protein expression, phosphorylation of the EGFR after EGF stimulation was unchanged (Fig. 8A, B) . In contrast, in response to EGF, phosphorylation of PLC␥ (Fig. 8C, D) was reduced in cells expressing exogenous GIT1 and SNX6, indicating that the altered cellular levels of EGFR receptor correlate with reduced EGFR signaling.
Lack of CC2 domain did not affect the binding of PIX and Cbl
It has been shown that GIT1 interacts with PIX (31, 32) , and PIX/Cool binding to the ubiquitin ligase Cbl has been shown to regulate EGFR trafficking (33, 34) . To evaluate the role of Cbl/PIX binding on EGFR degradation, GIT(WT) and GIT(⌬CC2) were overexpressed in HEK293 cells. Deletion of the GIT1 CC2 domain did not decrease the binding of PIX and Cbl (Supplemental Fig. 4) , although there was a substantial effect of GIT1(⌬CC2) on EGFR degradation, as shown in Fig. 7 . This result indicates that the change in EGFR expression observed with GIT1(⌬CC2) is most likely due to interaction with SNX6, not with PIX.
DISCUSSION
The major findings of the present study are that a novel interaction between GIT1 and SNX6 increases EGFR degradation and alters EGFR signaling, demonstrating a new function for GIT1 as a regulator of tyrosine kinase receptor trafficking. A direct interaction between the two proteins was demonstrated by interaction in a yeast two-hybrid assay and GST pulldown. The structural domain of GIT1 required for binding to SNX6 is located in the CC2 region. Binding of SNX6 to GIT1 is constitutive and is enhanced on EGF stimulation, as demonstrated by coprecipitation of the two proteins in VSMCs and HEK293 cells.
Previous studies have shown that GIT1 is localized to the recycling endosomal compartment, the early endosome, focal adhesions, the cell's leading edge, and small cytoplasmic complexes (4, 35) , whereas SNX6 localizes predominantly to early endosomes (14, 22, 23) . We demonstrate colocalization of GIT1 and SNX6 in vesicular structures by confocal microscopy. Furthermore, by cell fractionation it is evident that GIT1 and SNX6 colocalize to a light membrane fraction, overlapping with the early endosomal marker EEA1. These and previously published data strongly suggest that the interaction between SNX6 and GIT1 occurs in an early endosomal compartment.
There is a constitutive interaction between SNX6 and GIT1, which is increased 3-fold after stimulation with EGF for 60 min. This may be due to translocation of GIT1 to the endosomal compartment and also may be due to a conformational change in GIT1 (and/or SNX6), that facilitates binding, perhaps due to agonistinduced phosphorylation. Avian GIT1 shuttles between the plasma membrane and the endocytic compartment, suggesting a role for GIT1 in intracellular receptor trafficking (5) . SNXs increase the degradation of several receptors, including receptors for EGF, insulin, PDGF, transferrin, TGF, and the GPCR protease-activated receptor (PAR1) (13, 14, 22) . SNX1 decreases EGFR on the cell surface, due to an increase in the rate of constitutive and ligand-induced degradation (13) . In the present study, we demonstrate a role for GIT1 and SNX6 in accelerating degradation of the EGFR. Reduction of GIT1 expression using siRNA slowed ligandinduced EGFR degradation, demonstrating that GIT1 promotes EGFR degradation. We can eliminate the possibility that GIT1 increases EGFR internalization, because it is well established that GIT1 inhibits the internalization of a number of receptors at the plasma membrane, including the EGFR (1-3) .
We further showed that coexpression of SNX6 and GIT1 markedly decreased both basal and ligand induced EGFR expression levels, suggesting increased degradation of the EGFR. The reduction in basal and ligand-induced EGFR expression observed with exogenous SNX6 and GIT1 contrasts with the ligand-induced (no change in basal levels) EGFR degradation seen with GIT1 siRNA. This is presumably due to differences in experimental design (i.e., overexpression vs. knockdown). The EGFR undergoes constitutive endocytosis and is targeted for lysosomal degradation at a much slower rate than ligand-induced degradation (19) . When GIT1 and SNX6 are overexpressed, our data suggest this constitutive degradation is increased, leading to a decrease in basal EGFR levels. Given the increased interaction between GIT1 and SNX6 on EGF stimulation, the dominant physiological effect is likely to be on ligand-induced degradation, with a smaller effect on constitutive degradation. It is also possible that the ARF-GAP function of GIT1 could affect EGFR degradation. However, the finding that GIT1 (250 -770), lacking the ARF-GAP domain, has a similar effect as GIT1(WT) on EGFR degradation further supports the importance of the GIT1-SNX6 interaction. Notably, overexpression of SNX6 and GIT1(⌬CC2), which has a deletion of the SNX6 binding domain, did not increase EGFR degradation and actually increased EGFR expression levels. A potential role for a GIT1-PIX/Cool complex (31, 32) , in EGFR degradation is suggested by the fact that PIX/Cool binding to the ubiquitin ligase Cbl regulates EGFR trafficking (33, 34) . However, our data demonstrated that loss of the GIT1 CC2 domain did not affect binding of PIX (which likely binds via the SHD domain), excluding this mechanism. It is possible that GIT1(⌬CC2) can displace endogenous GIT1 from the intracellular vesicles, where it interacts with SNX6. Because SNXs increase degradation of receptors by increasing endosome to lysosome trafficking (13, 24, 28, 36) , it is likely that the GIT1 and SNX6 interaction in the early endosome modifies EGFR trafficking. This novel function of GIT1 is distinct from its role in inhibiting the internalization of GPCRs and RTKs that are endocytosed through the clathrin-coated pit pathway through its inactivation of ARF6 (1, 2) . Further studies will investigate the role of the GIT1 and SNX6 interaction on the degradation of GPCRs.
GIT1 is a scaffolding protein that binds many proteins, including focal adhesion kinase, paxillin, PLC␥, MEK1, and ERK1/2 (6 -8, 37) . GIT1 localizes these proteins to specific sites in the cell where they regulate localized activities and may be involved in the localization and stabilization of SNX6 in endosomes. GIT1 may also link SNX6 to other proteins and/or SNXs, because homodimerization and heterodimerization of SNXs have been reported and may be important for SNX function (23, 38) . A recent study suggests an important role for GIT1 in intracellular protein trafficking. GIT1 interacts with huntingtin, a scaffolding protein with a role in vesicle transport, whose abnormal function contributes to Huntington's disease (35) . GIT1 enhances huntingtin aggregation by recruitment of the protein into intracellular membranous vesicles. In brains affected by Huntington's disease, GIT1 is selectively cleaved, altering its regulation of huntingtin aggregation. The role of altered EGFR signaling in Huntington's disease has not been studied, but an indirect association between huntingtin and EGFR has been reported (39) . It will be of interest to determine the effect of GIT1 cleavage on the SNX6/GIT1 interaction and EGFR degradation.
EGFR trafficking is an important mechanism by which the pattern as well as duration of signal transduction can be changed (18, 19) . Therefore, the effect of the GIT1 and SNX6 interaction on the activity of the downstream EGFR signal PLC␥ was determined. Phosphorylation of PLC␥ was decreased on expression of exogenous GIT1 and SNX6, especially at longer time points when the interaction between the two is maximal. GIT1 acts as a scaffold for EGF-mediated MEK1-ERK1/2 and PLC␥ activation through direct interaction with these signaling proteins (6, 37) . Therefore, GIT1 functions at multiple cellular locations in the regulation of EGFdependent signaling cascades, with dual functions as a modulator of signaling and trafficking.
